The governmental funding will support the company's plans for a 1,350 participant trial that aims to further validate its protein-based cancer early detection assay.
The round, which was led by Formation Venture Engineering, will support commercialization of the company's SAAmplify-ɑSYN biomarker test as well as increased R&D.
The US Food and Drug Administration granted marketing clearances for multiple infectious disease tests and a blood culture sample preparation system, among other devices.
CyPath Lung is a laboratory-developed assay that uses self-collected sputum samples treated with a fluorescent compound that preferentially binds to cancer cells and cancer-related cells, San ...
The firm received de novo marketing authorization for its combination antigen test, and the developers of subsequent tests will be able to seek 510(k) clearance.
Canadian life sciences firm Microbix Biosystems announced recently that it has received CE marking under the EU’s In Vitro Diagnostics Regulation for 11 of its diagnostic assay quality assessment ...
The company is targeting its RPPA-based testing to biopharma firms as well as for clinical trial work and to clinicians to help guide therapy in cancer patients.